Search results
9 lip 2020 · These discordant recommendations raise the question of how background metformin might influence the CV benefits of GLP-1RAs. Using data from the LEADER trial, we sought to answer this question by exploring possible heterogeneity in the CV efficacy of liraglutide related to baseline metformin treatment .
4 maj 2020 · The double-blind, randomized, placebo-controlled LEADER trial assessed the CV safety of liraglutide in the context of standard care in patients with type 2 diabetes, HbA 1c ≥7% (≥53 mmol/mol), and a high risk for CVD (aged ≥50 years with established CVD or chronic kidney disease stage 3 or greater or ≥60 years with at least one risk ...
3 paź 2018 · LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo.
2 paź 2018 · The LEADER trial (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes) demonstrated a 13% significant relative risk reduction in major adverse cardiovascular events (MACE) with liraglutide versus placebo, both as add-on to standard-of-care treatment, in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. 8
30 lis 2017 · To the Editor: In reporting the results of the secondary analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, Mann et al....
1 sty 2016 · Abstract. Numerous explanations, classifications, theories and definitions about leadership, exist in the contemporary literature. Substantial effort has gone in to classify and clarify...
Published in 2016, the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial randomized 9,340 patients with type 2 diabetes and high CV risk to receive liraglutide or placebo. With a median follow-up of 3.8 years, liraglutide was associated with a significant reduction in CV mortality, nonfatal ...
